- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00968916
Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 in Patients With Solid Tumors
An Open-label, Dose Escalation, Safety and Pharmacokinetics Phase 1 Study With AVE8062 Administered as a 30-minute Intravenous Infusion Every 3 Weeks in Patients With Advanced Solid Tumors.
Primary objective: To determine the maximum tolerated dose based on the incidence of dose limiting toxicity and the maximum administered dose of AVE8062 administered every 3 weeks in patients with advanced solid tumors.
Secondary objectives:
- To assess the overall safety profile of the drug.
- To characterize the pharmacokinetic profile of AVE8062 and its active metabolite RPR 258063.
- To evaluate anti-tumor activity of the drug.
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Osaka Sayama-Shi, Japan
- Sanofi-Aventis Investigational Site Number 392002
-
Sunto-Gun, Japan
- Sanofi-Aventis Investigational Site Number 392001
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Advanced solid tumor that has become refractory to conventional treatment or for which no standard therapy exists.
- Patients with signed and dated Institutional Review Board (IRB)-approved patient informed consent form (ICF) prior to enrollment in the study.
Exclusion Criteria:
- Eastern Cooperative Oncology Group performance status > or = 2.
- Life expectancy of less than 12 weeks.
- Concurrent treatment with any other anticancer therapy, including chemotherapy, immunotherapy, radiotherapy, targeted therapy, gene therapy, or patients planning to receive these treatments during the study.
- Absence of histologically or cytologically proven cancer.
- Male patients who do not agree with contraception. Absence of negative serum/urinary pregnancy test within the 7 days prior to the enrollment in the study for female patients with childbearing potential. Patients must be post-menopausal, surgically sterile, or using "effective contraception" (the definition of "effective contraception" will be based on the judgment of the investigator).
- Washout period of less than 28 days from prior antitumor therapy (chemotherapy, targeted agents, immunotherapy and radiotherapy) or any investigational treatment, except for nitrosoureas, mitomycin which may not be used up to 42 days prior to the first cycle. No washout period is required for hormonal therapy, however, it must be discontinued before the first cycle.
- Not recovered from all previous therapies (radiation, surgery, and medications). Adverse events related to previous therapies must be National Cancer Institute Common Terminology Criteria grade < or = 1 (or alopecia < or = grade 2) at screening or returned to the subject's baseline prior to their most recent previous therapy.
- Symptomatic brain metastases and carcinomatous leptomeningitis.
Other serious illness or medical conditions:
- Existence of significant neurologic or psychiatric disorders impairing the ability to obtain consent.
- Active infection.
- Other serious illness not controlled by adequate treatment.
Inadequate organ function including:
- Absolute neutrophils counts<1.5 x 10^9/L
- Platelets counts<100 x 10^9/L
- Hemoglobin<9.0 g/dL (without red blood cells transfusion during 28 days prior to the test)
- Calculated creatinin clearance<60 ml/min
- Total bilirubin > or = 1.5 mg/dL
- Alanine aminotransferase/aspartate aminotransferase>1.5 times the upper normal limits of the institutional norms.
- Alkaline phosphatase (AP)>2.5 times the upper normal limits of the institutional norms. An increase of AP up to grade 2 would be accepted only if this increase is related to the presence of bone metastases. Bone specific isoenzyme AP should be greater than the pathological limit defined by the manufacturer as a sign of bone metastases.
- Documented medical history of myocardial infarction, documented angina pectoris, arrhythmia especially severe conduction disorder such as second or third degree atrio-ventricular block, stroke, or history of arterial or venous thrombo-embolism within the past 180 days requiring anticoagulants.
- Patient with a left ventricular ejection fraction<50% by echocardiography.
- Patient with a baseline QTc interval of >0.45, or family history of Long QT Syndrome
- Patient with uncontrolled hypertension and patient with organ damage related to hypertension such as left ventricular hypertrophy or grade 2 ocular funduscopic changes or kidney impairment.
- Patient with growing vessel disease (eg age-related macular degeneration, diabetic retinopathy, rheumatoid arthritis), or ongoing wound healing process. Patient should be enrolled in the study at least 28 days after surgery.
- 12-lead Electrocardiogram: ST- and T-wave changes suggesting ischemia
- Hypertension defined as systolic blood pressure (BP)>140 mmHg or diastolic BP>90 mmHg on two repeated measurements at 30 minutes intervals.
- Patient with one or more episodes of ventricular tachycardia with 3 or more consecutive premature beats, with a frequency > or = 180 beats/min.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 1
Level 1: 15.5 mg/m2 of AVE8062 will be administered once in every 3 weeks, with 30-minute intravenous infusion and continued until unacceptable toxicity or disease progression or patient refusal Level 2: 25 mg/m2 of AVE8062 will be administered once in every 3 weeks, with 30-minute intravenous infusion and continued until unacceptable toxicity or disease progression or patient refusal Level 3: 35 mg/m2 of AVE8062 will be administered once in every 3 weeks, with 30-minute intravenous infusion and continued until unacceptable toxicity or disease progression or patient refusal Level 4: 50 mg/m2 of AVE8062 will be administered once in every 3 weeks, with 30-minute intravenous infusion and continued until unacceptable toxicity or disease progression or patient refusal |
Pharmaceutical form: injection solution Route of administration: intravenous infusion |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Dose limiting toxicity at Cycle 1
Time Frame: 21 days
|
21 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Global safety profile based on treatment emergent adverse events, serious adverse events, and laboratory abnormalities
Time Frame: all cycles
|
all cycles
|
Pharmacokinetic parameters of AVE8062: Cmax, AUC, CL, Vss, and t1/2
Time Frame: Day 1 and 2 of Cycle 1, and day 1 of subsequent cycles
|
Day 1 and 2 of Cycle 1, and day 1 of subsequent cycles
|
Pharmacokinetic parameters of AVE8062's active metabolite RPR258063: Cmax, AUC, t1/2, and Metabolic ratio
Time Frame: Day 1 and 2 of Cycle 1, and day 1 of subsequent cycles
|
Day 1 and 2 of Cycle 1, and day 1 of subsequent cycles
|
Objective tumor response as defined by the Response Evaluation Criteria in Solid Tumors in evaluable patients
Time Frame: from patient informed consent to end of treatment
|
from patient informed consent to end of treatment
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TED10967
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
RemeGen Co., Ltd.CompletedMetastatic Solid Tumor | Locally Advanced Solid Tumor | Unresectable Solid TumorAustralia
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
Shenzhen Ionova Life Sciences Co., Ltd.Merck Sharp & Dohme LLCRecruitingCancer | Solid Tumor, Adult | Solid Carcinoma | Solid Tumor, Unspecified, Adult | Cancer Metastatic | Tumor, SolidUnited States
-
BeiGeneRecruitingSolid Tumor | Advanced Solid TumorUnited States, New Zealand, Australia, China
Clinical Trials on ombrabulin (AVE8062)
-
SanofiCompletedNeoplasmsFrance, Italy, Switzerland
-
SanofiCompletedSarcomaBelgium, Hungary, United States, Brazil, France, India, Italy, Serbia, Spain, United Kingdom
-
SanofiCompleted
-
SanofiCompletedNon-small Cell Lung CancerFrance, Romania, Poland, Croatia, Korea, Republic of, Italy, Chile, United States, Australia, Germany, Russian Federation, Serbia, Ukraine
-
SanofiCompleted
-
SanofiCompleted
-
SanofiCompleted
-
SanofiCompleted
-
SanofiCompletedOvarian Cancer RecurrentBelgium, Russian Federation, Poland, Spain, Czech Republic, United States, France, Germany, Italy, Ukraine
-
SanofiCompletedNeoplasms, MalignantFrance, United Kingdom, Italy